Hepatic steatosis detected by ultrasonography as a predictor of insulin resistance in obese patients by Isaksen, Victoria Therese
 
 
Hepatic Steatosis Detected by Ultrasonography as a Predictor of 












Research group of Gastroenterology and Nutrition, Department of Clinical Medicine,  
UiT The Arctic University of Norway, Tromsø, Norway  
2




Victoria Therese Isaksen 
Faculty of Health Sciences 
UiT The Arctic University of Tromsø 





Running title: Liver steatosis and insulin resistance risk 
Key words: body mass index, hepatorenal index, HOMA-IR, metabolic syndrome, morbid 




Background and aims: The metabolic syndrome (MetS) is a worldwide health issue. Components 
of MetS are obesity, hypertension, insulin resistance/type 2 diabetes and dyslipidaemia. Non-
alcoholic fatty liver disease (NAFLD) is closely related to the MetS, and particularly to insulin 
resistance. A significant feature of NAFLD is the presence of hepatic steatosis, which can be 
assessed by ultrasonography, by measuring the hepatorenal index (HRI), a comparison of liver 
and kidney acoustic echo densities. This study aims to investigate if HRI can predict insulin 
resistance.  
Patients and methods: Ninety participants from the obesity clinic and the Sixth Tromsø Study 
were included. Homeostasis Model Assessment of Insulin Resistance (HOMA1-IR), body mass 
index (BMI) and HRI were measured. Steatosis was classified as mild (HRI 1.05-1.24), moderate 
(HRI 1.25-1.64) or severe (HRI ≥1.65).  ROC analyses were performed, detecting insulin 
resistance at HOMA1-IR cut-off values 2.3 and 2.5. Groups of participants with BMI ≥30  
(n = 46) and BMI ≥35 (n = 27) were analysed specifically. 
Results: HRI at level 1.11 had sensitivity = 0.92 and specificity = 0.56 for predicting insulin 
resistance in all participants, whereas HRI at level 1.42 had sensitivity = 0.29 and  
specificity = 0.94. For BMI ≥30, HRI at level 1.11 had sensitivity = 0.94 and specificity = 0.54, 
and HRI = 1.42 had sensitivity = 0.33 and specificity = 0.96. For BMI ≥35, HRI = 1.17 had 
sensitivity = 0.93 and specificity = 0.77, whereas HRI = 1.42 had a sensitivity = 0.29 and a 
specificity = 0.92. (All test property values calculated for HOMA1-IR ≥2.3). 
Conclusion: Mild hepatic steatosis diagnosed by ultrasound is a good predictor for diagnosing 




Obesity is a major worldwide health issue due to its association with the metabolic syndrome 
(MetS). In 2008, more than 1.4 billion adults were overweight. Of these, about 500 million were 
obese (1). Components of the MetS are: hypertension, insulin resistance/type 2 diabetes and 
dyslipidaemia (hypertriglyceridemia and low levels of high density lipoproteins (HDL)) (2, 3).  
Non-alcoholic fatty liver disease (NAFLD) is closely associated with the MetS, and is in some 
definitions considered part of the MetS. NAFLD is the most common type of liver disease in the 
developed world today, with a prevalence of approximately 30% (4, 5).  
The hepatic lipid metabolism is vulnerable to metabolic dysfunction, resulting in the 
accumulation of lipid droplets in the hepatocyte. The ‘two-hit theory’ is a well-known model by 
Day et al(6), for describing the pathogenesis of NAFLD. The ‘first hit’ is a hepatocellular lipid 
accumulation due to an imbalance of lipid uptake and combustion. The ‘second hit’ is defined as 
a hepatocellular inflammation (NASH), due to imbalance between pro- and anti-inflammatory 
factors (4, 6).  
One hypothesis on the cause of the first hit is glycolysis overload by a high dietary fructose 
intake, causing an increase in de novo lipogenesis and the accumulation of lipid droplets. The 
same mechanism is used to explain hepatic insulin resistance and ultimately the inflammation (7, 
8).  
The most common explanation of the pathophysiologic mechanism is, however, one or more of 
the following mechanisms: an increased inflow of free fatty acids due to insulin resistance in 
adipose tissue, altered processing of dietary lipids in the hepatocyte, impaired export of lipids 
and increased de novo lipogenesis (4, 5). It has also been suggested that the adipocyte’s volume 
and production of adipokines are closely related, with the presence of and progression of 
NAFLD through increased inflammation. (5, 9) 
 
 
Insulin resistance (IR) is considered to be the most important part of the MetS, being part of its 
pathophysiologic mechanism (10,11). IR is characterized by impaired lowering of blood glucose 
through a reduced uptake in muscles and lack of insulin’s effect on reducing endogenous glucose 
production in liver. IR is also characterized by impaired insulin effect on lipid and protein 
metabolism, and also impaired effect on a number of other organs (10, 12).  
A common way of assessing insulin resistance is by the Homeostasis model assessment of 
insulin resistance (HOMA1-IR) (13, 14) 
Previous studies have shown that the optimal cut-off value of HOMA1-IR is 2.3 for detecting 
insulin resistance and MetS (sensitivity 77 % and specificity 67 %). The updated HOMA2-IR is 
more accurate, correcting for feedback relationships between insulin resistances in different 
organs. The optimal cut-off value for HOMA2-IR is 1.4, (sensitivity 79 % and specificity 62 %). 
However, HOMA2-IR has a limited range of reliable values, and calculating the index is much 
more complicated (15). 
A second method for assessing insulin resistance is by Whole Body Insulin Sensitivity Index 
(WBISI), calculated from the fasting and mean postprandial values of blood glucose and serum 
insulin during an Oral Glucose Tolerance Test (OGTT). The formula used for calculating insulin 
sensitivity is Matsuda’s ISI (16). 
The gold standard for diagnosing hepatic steatosis is by liver biopsy (17), which also is the only 
way of diagnosing the presence of steatohepatitis. Liver biopsy, however, remains an invasive 
procedure with a risk of complications, and the need for biopsy in the diagnosis of NAFLD is 
much debated (18).  
Increased levels of transaminases and γ-GT are used as an indicator of NAFLD when biopsy is 
contraindicated or not available. They are often combined with radiological methods like CT, 
MRI and ultrasound, where ultrasound is the cheapest method with the lowest risk of 
complications and no radiation dose, and therefore often preferred. Subjective assessment of 
steatosis in ultrasound does have a relatively large inter- and intraobserver variability. A way of 
 
reducing this variability is by measuring the liver and kidneys’ echogenicity on a grayscale from 
0- 255, and using the mean value for computing a hepatorenal index (HRI)(19). HRI is a tool of 
quantifying the steatosis that is more reliable than subjective assessment alone. 
Normally the liver and kidney cortex has the same echogenicity. Normal HRI is therefore in the 
range from 1.00 to 1.04. Hepatic steatosis is classified in mild (HRI 1.05-1.24), moderate (1.25-
1.64) or severe steatosis (≥1.65) (19). 
Insulin resistance in obese individuals is crucial for the risk of further development of the 
Metabolic Syndrome, and the presence of hepatic steatosis and insulin resistance is closely 
linked. Although the HOMA1-IR is relatively simple to calculate both in general practice and in 
specialist care, it tends not to be in mind of the clinician, unless there are other factors suggesting 
an underlying insulin resistance. Ultrasonography, being a risk-free procedure that is simple to 
perform, would be the natural choice for a screening procedure, and therefore, it is necessary to 
know its test properties.  
 
Aim of study: To examine whether hepatic steatosis, quantified by HRI, is usable as a test for 










Materials and Methods 
Participants were included both from a study performed at the obesity clinic at the University 
hospital of North Norway, and from a follow-up study on slightly elevated transaminases in the 
Sixth Tromsø Study (Figure 1). The Sixth Tromsø Study is previously described by Eggen et al. 
(20). All participants signed a written consent, which included permission to use their data for 
follow-up studies. The study performed at the obesity clinic was approved by The Regional 
Committee of Medical Ethics of North Norway, including approval of a bio bank. 
Access to data and participants for the follow-up study for the Sixth Tromsø Study was approved 
by the Tromsø Study organisation. The follow-up study was covered by the main ethical 
approval given for the Sixth Tromsø Study by the Regional Committee of Medical Ethics of 
North Norway.  
Patients at the obesity clinic with a BMI of 30 or more were included in the study. Exclusion 
criteria were medical treatment of diabetes mellitus, severe heart disease or severe kidney failure. 
These participants underwent an Oral Glucose Tolerance Test (OGTT), where the participants 
drank 75 g of glucose solved in water. Fasting and postprandial blood glucose and serum insulin 
levels were measured at 30-minute intervals, and HOMA1-IR and Matsuda’s ISI was calculated:  
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Height, weight and blood pressure were recorded, blood samples for measurement of liver 
transaminases and γ-glutamyl transferase were collected, and abdominal ultrasound was 
performed as described below.  
The participants included from the Tromsø Study follow-up were divided into three groups: 
participants with either transaminases or γ-glutamyl transferase of 2x Upper Limit of Normal 
 
(ULN), participants with values between ULN and 2x ULN, and a selection of participants with 
normal values, matched for sex and age of the first two groups.  
The group with liver enzyme levels of 2x ULN or more was followed up during the first few 
months after the Tromsø Study visits in 2008. The two other groups were followed up during 
2013/2014. The same variables were recorded for all three groups: height, weight, transaminase 
and γ-glutamyl transferase levels, and fasting blood glucose, serum insulin, and triglyceride 
levels. Abdominal ultrasound was performed with measurement of HRI. We also collected data 
for blood pressure from the Tromsø study visits.  
Abdominal ultrasound was performed using a Hitachi EUB-6500 HW with a 5 MHz convex 
EUP-C524 transducer (Hitachi Medical Corporation, Tokyo, Japan). Hepatic and renal 
parenchymal echogenic density on a grayscale (0-255) was recorded with the built-in histogram 
function. Values below 1.0 were corrected to 1.0. An average of three repeated measurements 
was used to calculate hepatorenal index (HRI) by the formula:  
      
                       
                        
 
 All statistical analyses were carried out using IBM SPSS Statistics, version 21. ROC analyses 
were performed, detecting insulin resistance at HOMA1-IR values 2.3 and 2.5. Groups of 
participants with BMI ≥ 30 (n = 46) and BMI ≥ 35 (n = 27) were analysed specifically, in 




We included 90 participants in the whole study (20 men and 70 women), of which 22 patients 
were included from the obesity clinic and 68 participants from the sixth Tromsø Study as shown 
in Figure 1. Median age for the study population as a whole was 64 years (range 21- 82), and 
median BMI was 30 (range 19.3- 51.2). Baseline characteristics are shown in Table 1. 
<insert figure 1> 
<insert table 1> 
 
For the participants included from the obesity clinic, we calculated both HOMA1-IR and WBISI, 
in order to verify the reliability of HOMA1-IR in our dataset. Correlation between HOMA1-IR 
and WBISI is shown in Figure 2. 
 
<insert figure 2> 
 
 
Sensitivity and specificity values for different HRI levels for detecting a pathological HOMA1-
IR are shown in Table 2. Summarised, the test has a high sensitivity and a relatively low 
specificity for HRI values corresponding to mild hepatic steatosis (HRI = 1.11), and a low 
sensitivity with a high specificity for HRI values corresponding to moderate hepatic steatosis 
(HRI = 1.42). Corresponding ROC curves are shown in Figures 3a – d.  
 
<insert table 2> 
 
<insert figure 3 a-d> 
 
Discussion 
In light of the obvious relationship between NAFLD and the MetS, and also in light of the many 
and severe complications of metabolic dysfunction, having good screening methods for detecting 
early signs of the MetS is of importance.  
We chose the HOMA1-IR for this study because of its better applicability compared to the 
HOMA2-IR. Previous studies have shown an optimal HOMA1-IR cut-off value of 2.3. Our 
results show that using HRI as a screening test for detecting insulin resistance (IR) is possible, 
but it should only be used in groups where the prevalence of IR is high, that is, in people with a 
BMI of 30 or more. In this group, mild steatosis (HRI ≥ 1.11) diagnosed by ultrasound will 
detect 94 % of patients with a HOMA-IR of 2.0 or more. However, the specificity of the test is 
low (54 %). Therefore, this test will identify patients with high risk of having IR. We also 
calculated test properties for HOMA-IR levels of 2.0 and 2.5, because the clinical significance of 
the HOMA-IR limit may vary, depending on your goals. A limit of 2.0 detects all patients with a 
genuine insulin resistance, but renders too many patients with a false positive result. A cut-off 
limit of 2.0 is also not clinically relevant because of a large degree of overlap with normal 
HOMA-IR values in the population. The results of this analysis are therefore not described in 
this paper. A limit of 2.5 gives a more clinically applicable HOMA-IR value, but with a higher 
number of false negative results. 
In a previous study of the test properties of HRI, show that a HRI cut-off value of 1.49 has a 
sensitivity of 100 % and a specificity of 91 % for detecting a 5 % steatosis, diagnosed by liver 
biopsy (19). Our results show that a HRI cut-off at 1.42 will have a specificity of 91 % in the 
group with BMI of 30 or more. A HRI result of 1.49 will therefore be diagnostic, both for having 
an actual hepatic steatosis, and also an actual insulin resistance.  
 
Although a HRI cut-off level of 1.11 will give many false positive results, this is acceptable in a 
screening test, since the verification of IR is relatively simple through calculating HOMA-IR 
and/or WBISI. 
One of the strengths of this study is that the study population is similar to the patient group that 
will be relevant for this screening, both because of overweight/obesity and because of 
pathological liver blood tests. An extrapolation to the general population is however not possible.  
We did not perform liver biopsy to confirm the results of the ultrasound examination. Therefore, 
one cannot say for certain that the participants with HRI <1.49 have hepatic steatosis. The 
correlation between the actual steatosis and insulin resistance is beside the scope of this article, 
since this correlation is generally accepted.  
One of the weaknesses of the HRI as a means of assessing steatosis is its variability. There is a 
certain degree of both inter- and intraobserver variability, but the results are also dependent on 
the type of ultrasound equipment used. HRI values in different studies may not be directly 
comparable as a result of this. Also, in later ultrasonography models, one of the features 
available is the option to highlight the liver tissue over other tissues, which will influence on the 
results. One needs to be aware of this as a source of bias when choosing this method.  
The results of our study need confirmation by further studies with more patients/participants 
included, since the obese group, and particularly the group with morbid obesity had few cases 
with insulin resistance. 
Conclusion: Mild hepatic steatosis (HRI ≥1.11) diagnosed by ultrasound is a good test for 
detecting insulin resistance, especially in obese patients. The specificity of the test is however 
low. Patients with a hepatorenal index of 1.42 or more are likely to have a true positive result for 
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Figure 1: Flowchart of included participants from the Sixt Tromsø Study and the 
Obesity clinic, UNN 
Figure 2:  Correlation between WBSI and HOMA-IR for 18 overweight or obese 
participants.  
Spearman Correlation: -0.922 (p <0.001) (two-tailed analysis). 
Figure 3a: ROC curve of HOMA-IR >2.3 by hepatorenal index in participants with 
BMI ≥30 
Figure 3b: ROC curve of HOMA-IR >2.3 by hepatorenal index in participants with 
BMI≥35 
Figure 3c: ROC curve of HOMA-IR >2.5 by hepatorenal index in participants with 
BMI ≥30 
Figure 3d: ROC curve of HOMA-IR >2.5 by hepatorenal index in participants with 


















































































 Variables Inclusion groups 
  
Obesity clinic  Sixth Tromsø Study 
N Median(SD) Range N Median (SD) Range 
Age, years 22 43,0 (12,76) 21-69 68 66,0 (10,84) 32-82 
Height, cm 21 168,0 (6,79) 156-179 68 166,0 (9,08) 141-189 
Weight, kg 22 113,0 (16,13) 83,5-148,0 68 81,3  (15,51) 50,6-123,5 
Systolig BP, 
mmHg 
22 126,0 (11,36) 112-159 68 137,0 (22,07) 96-213 
Diastolic BP, 
mmHg 
22 74,0 (8,16) 62-94 68 78,0 (8,42) 50-102 
BMI, kg/m
2
 21 41,4 (5,21) 31,8-51,2 68 28,0 (5,35) 19,3-45,6 
ASAT, U/L 22 18,0 (9,32) 12,0-53,0 66 29,5 (1,23) 14,0-71,0 
ALAT, U/L 4 38,5 (6,70) 29,0-45,0 66 39,0 (20,36) 14,0-102,0 
γ-GT, U/L 21 29,0 (45,72) 13,0-198,0 65 82,0 (82,74) 14,0-398,0 
ALP, U/L 4 88,0 (9,22) 80,0-99,0 66 81,0 (38,96) 36,0-322,0 




HOMA-IR ≥2.3  
 All participants (n = 24) BMI ≥30 (n = 18) BMI ≥35 (n = 14) 
HRI cut-
off level 
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
1.11 0.92 0.56 0,94 0.54   
1.17   0.89 0.71 0.93 0.77 
1.42 0.29 0.94 0.33 0.96 0.29 0.92 
 
HOMA-IR ≥2.5  
 All participants(n = 20) BMI ≥30 (n =14) BMI> 35 (n = 11) 
HRI cut-
off level 
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
1.11 0.90 0.53     
1.17   0.86 0.62 0.91 0.62 





Table 2: Sensitivity and specificity for different levels of HRI for the prediction of 
pathological HOMA1-IR 
